Key Takeaways Merck shares have dropped 14% in 2025, underperforming the industry, sector and the S&P 500.Keytruda sales rose 7% in H1 2025, but Gardasil fell 48% on weak China demand.MRK's $10B pending Verona Pharma deal adds Ohtuvayre, bolstering its cardio-pulmonary pipeline.Merck (MRK) is a prominent pharmaceutical company with a strong position in oncology. Its blockbuster drug, Keytruda, and new products have been driving sales. Animal health is also contributing to growth. Merck has been making meani ...